Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press9410.17650/1726-9776-2013-9-2-53-56PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫCURRENT POSSIBILITIES OF TREATMENT FOR VISCERAL METASTASES IN PATIENTS WITH METASTATIC CASTRATION-REFRACTORY PROSTATE CANCERСОВРЕМЕННЫЕ ВОЗМОЖНОСТИ ЛЕЧЕНИЯ ВИСЦЕРАЛЬНЫХ МЕТАСТАЗОВ У БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ КАСТРАЦИОННО-РЕФРАКТЕРНЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫGovorovA. V.ГоворовА. В.
Russian Federation

Department of Urology

кафедра урологии

alexgovorov@newmail.ruMoiseenkoT. N.МоисеенкоТ. Н.
Russian Federation

Department of Urology

кафедра урологии

alexgovorov@newmail.ruMoscow State University of Medicine and Dentistry named after A.I. EvdokimovМГМСУ им. А.И. Евдокимова МЗ РФ300620139253562707201427072014https://oncourology.abvpress.ru/oncur/article/view/94

Medications increasing the survival of patients with metastatic castration-refractory prostate cancer (CRPC) are lacking today. In the past 3 years, in the pharmaceutical market there have been a few novel drugs to treat progressive prostate cancer. Abiraterone acetate is an androgen synthesis inhibitor, which is also used to increase the survival of patients with metastatic CRPC that progresses after chemotherapy. The results of treatment for metastatic CRPC depend on a number of factors. Visceral metastases are poor predictors of the course of the disease. The results of abiraterone acetate treatment were analyzed in CRPC patients with visceral metastases.

Лекарственных препаратов, увеличивающих продолжительность жизни пациентов с метастатическим кастрационно-рефрактерным раком предстательной железы (КРРПЖ), на сегодняшний день недостаточно. За последние 3 года на фармацевтическом рынке появилось несколько новых препаратов, направленных на лечение прогрессирующего РПЖ. Абиратерона ацетат является ингибитором биосинтеза андрогенов и применяется в том числе для увеличения продолжительности жизни пациентов с метастатическим КРРПЖ, прогрессирующим после химиотерапии. Результаты лечения метастатического КРРПЖ зависят от ряда факторов. Висцеральные метастазы относятся к факторам неблагоприятного прогноза течения заболевания. Нами проведен анализ результатов лечения больных КРРПЖ с висцеральными метастазами с использованием абиратерона ацетата.

castration-refractory prostate cancerabiraterone acetatevisceral metastasesкастрационно-рефрактерный рак предстательной железыабиратерона ацетатвисцеральные метастазы1. Armstrong A.J., Garrett-Mayer E., de Wit R. et al.Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research 2010;16:203–11.Armstrong A.J., Garrett-Mayer E., de Wit R. et al.Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clinical Cancer Research 2010;16:203–11.2. Kelly W.K., Halabi S., Carducci M. et al. Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534–40.Kelly W.K., Halabi S., Carducci M. et al. Randomized, double-blind, placebocontrolled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30(13):1534–40.3. O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17alphahydroxylase/ C (17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317–25.O'Donnell A., Judson I., Dowsett M. et al. Hormonal impact of the 17alphahydroxylase/ C (17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 2004;90(12):2317–25.4. Dorff T.B., Crawford E.D. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 2013;24(1):31–8.Dorff T.B., Crawford E.D. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol 2013;24(1):31–8.5. Keizman D., Huang P., Carducci M.A., Eisenberger M.A. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate 2012;72(4):461–7.Keizman D., Huang P., Carducci M.A., Eisenberger M.A. Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression. Prostate 2012;72(4):461–7.6. Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92.Fizazi K., Scher H.I., Molina A. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012;13(10):983–92.7. Ryan C.J., Smith M.R., de Bono J.S. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012;368:138–48.Ryan C.J., Smith M.R., de Bono J.S. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2012;368:138–48.8. De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. NEJM 2011;364:1995–2005.De Bono J.S., Logothetis C.J., Molina A. et al. Abiraterone and increased survival in metastatic prostate cancer. NEJM 2011;364:1995–2005.9. Suttman H., Mulders P., Molina A. et al. Eur Urol 2013; Suppl: abstr.105.Suttman H., Mulders P., Molina A. et al. Eur Urol 2013; Suppl: abstr.105.10. Schweizer M.T., Antonarakis E.S. Abiraterone and other novel androgendirected strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012;4(4):167–78.Schweizer M.T., Antonarakis E.S. Abiraterone and other novel androgendirected strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol 2012;4(4):167–78.11. Huang X., Chau C.H., Figg W.D. Challenges to improved theraupeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 2012;5:35.Huang X., Chau C.H., Figg W.D. Challenges to improved theraupeutics for metastatic castrate resistant prostate cancer: from recent successes and failures. J Hematol Oncol 2012;5:35.